BI 764532
Boehringer Ingelheim
['sclc']
potent drugs targeting dll3 are highly needed. bi764532, a dll3/cd3 t-cell engager, is active but quite toxic in an highly selected population, eligible to phase i trials. in real life, our pts with sclc are frail, and toxicities might be much even more challenging. #asco23 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.